Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP992953priorityCriticalpatent/ECSP992953A/en
Publication of ECSP992953ApublicationCriticalpatent/ECSP992953A/en
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
La presente invención está orientada a un polpétido que comprende una miteina de IL-2 humana numerada de acuerdo con la IL-2 de tipo salvaje en la cual dicha IL-2 humana está sustituida en por lo menos una de las posiciones 20, 88 o 126, con la cual dicha meteína activa células T con mayor preferencia con respecto a las cuales NK E1 D2OH e I, N88G I, y R, en particular, tienen una actividad diferencial para las células T, mucho mayor que la IL-2 nativa, con una toxicidad in vivo asociada predicha, reducida la invención también provee polinucleótidos que codifican las muteínas de la invención, vectores que contienen los polinucleótidos, células hospedantes transformadas, composiciones farmacéuticas que contienen las muteínas y métodos terapéuticos de tratamiento.The present invention is directed to a polypeptide comprising a human IL-2 mitein numbered according to wild-type IL-2 in which said human IL-2 is substituted at least one of positions 20, 88 or 126, with which said metein activates T cells more preferably with respect to which NK E1 D2OH and I, N88G I, and R, in particular, have a much higher differential activity for T cells than native IL-2 With reduced predicted associated in vivo toxicity, the invention also provides polynucleotides encoding the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions containing the muteins, and therapeutic methods of treatment.
ECSP9929531999-05-131999-05-13
SELECTIVE IL-2 AGONISTS AND ANTAGONISTS (CASE 5038P1-EC)
ECSP992953A
(en)
"A POLYPEPTIDE THAT INCLUDES A MUTEINE OF INTERLEUQUINA-2-- HUMANA, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, A POLINUCLEOTIDE, A PROCARIOT CELL, AN ISOLATED EUCARIOT CELL, AND A VECTOR"
Use of an active ingredient, pharmaceutical composition, methods for inducing g-csf secretion within an individual's body for therapeutic treatment, for inducing proliferation or differentiation of bone marrow or white blood cells in an individual for prevention or treatment. leukopenia, for the prevention or treatment of toxic side effects of a drug, to inhibit abnormal cell growth, to treat cancer, and to use a3rag
METHOD TO SUPPRESS AUTOIMMUNE DESTRUCTION OF PANCREATIC BETA CELUIAS, PHARMACEUTICAL FORMULATION, PROPHYLAXIS METHOD, METHOD TO PREVENT THE SURGE OF TYPE 1 DIABETES AND METHOD FOR TREATING A MAMMAL
POLYCYCLIC DIHYDROTIAZOL COMPOUNDS, PROCEDURES FOR THE PREPARATION, MEDICATION, PROCEDURE FOR THE PREPARATION OF SUCH MEDICINAL PRODUCT AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT.
P277 peptide analogs and pharmaceutical compositions and preparations comprising them for the treatment or diagnosis of diabetes and a kit for diagnosing.